Effects of Adjuvant Systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats

Regulatory Toxicology and Pharmacology

Volumn 73, Issue 1, 2015, Pages 116-125

  Segal, Lawrence ^a   Roger, Virginie ^b   Williams, Colin ^c   Destexhe, Eric ^a   Garçon, Nathalie ^a,d  

^a GSK   (Belgium)

^b WIL Research Europe Lyon   (France)

^c HUNTINGDON LIFE SCIENCES   (United Kingdom)

^d BIOASTER   (France)

Author keywords

Adjuvant System; AS01; AS03; AS04; AS15; Cardiovascular; Dog; Rat; Respiratory; Telemetry

Indexed keywords

ADJUVANT; ARSENIC ACID; ARSENIC ACID DERIVATIVE; ARSENIC TRIOXIDE; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BEAGLE; BODY TEMPERATURE; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; FOOD INTAKE; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QTC INTERVAL; RAT; RESPIRATORY FUNCTION; TELEMETRY; TOXICITY TESTING; ANIMAL; ANIMAL MODEL; BLOOD PRESSURE; BREATHING; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; DOG; DRUG EFFECTS; PROCEDURES; WISTAR RAT;

CANIS FAMILIARIS; RATTUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; DOGS; HEART RATE; MALE; MODELS, ANIMAL; RATS; RATS, WISTAR; RESPIRATION; TELEMETRY;

EID: 84936934979     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.06.003     Document Type: Article

References (50)

1. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
2. Authier S., Legaspi M., Gauvin D., Troncy E. Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys. Regul. Toxicol. Pharmacol. 2009, 55:229-235.
3. Baird T.J., Bailie M., Patrick D.J., Moddrelle D., Yoder J., Gauvin D.V., Dalton J.A. Influence of surgically implantable telemetry solutions on in-life and post-mortem toxicology endpoints. J. Pharmacol. Toxicol. Methods 2013, 67:148-161.
4. Baldrick P., Richardson D., Elliott G., Wheeler A.W. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul. Toxicol. Pharmacol. 2002, 35:398-413.
5. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2011, 10:499-511.
6. Brichard V.G., Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin. Biol. Ther. 2008, 8:951-968.
7. Chiang A.Y., Holdsworth D.L., Leishman D.J. A one-step approach to the analysis of the QT interval in conscious telemetrized dogs. J. Pharmacol. Toxicol. Methods 2006, 54:183-188.
8. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 2010, 667:111-123.
9. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., Kielland A., Vosters O., Vanderheyde N., Schiavetti F., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant System, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 2009, 183:6186-6197.
10. Didierlaurent A.M., Collignon C., Bourguignon P., Wouters S., Fierens K., Fochesato M., Dendouga N., Langlet C., Malissen B., Lambrecht B.N., et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J. Immunol. 2014, 193:1920-1930.
11. Ebensen T., Guzmán C.A. Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Hum. Vaccin. 2008, 4:13-22.
12. EMEA Note for guidance on preclinical pharmacological and toxicological testing of vaccines. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP) 1995, issued as CPMP/SWP/465/95.
13. EMEA ICH topic S7A. Note for guidance on safety pharmacology studies for human pharmaceuticals. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 2000, issued as CPMP/ICH/539/00.
14. EMEA ICH topic S7B. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Step 5. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 2005, issued as CPMP/ICH/423/02.
15. Fridericia L.S. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann. Noninvasive Electrocardiol. 2003, 8:343-351.
16. Garçon N. Preclinical development of AS04. Methods Mol. Biol. 2010, 626:15-27.
17. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant Systems. Expert Rev. Vaccines 2011, 10:471-486.
18. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 2007, 6:723-739.
19. Garçon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an adjuvant system containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 2012, 11:349-366.
20. Hanton G., Rabemampianina Y. The electrocardiogram of the Beagle dog: reference values and effect of sex, genetic strain, body position and heart rate. Lab. Anim. 2006, 40:123-136.
21. Japan Ministry of Health and Welfare Guidelines for General Pharmacology Studies 1991, PAB/NDD Notification.
22. Karjalainen J., Viitasalo M. Fever and cardiac rhythm. Arch. Intern. Med. 1986, 146:1169-1171.
23. Kearney K., Metea M., Gleason T., Edwards T., Atterson P. Evaluation of respiratory function in freely moving Beagle dogs using implanted impedance technology. J. Pharmacol. Toxicol. Methods 2010, 62:119-126.
24. Kensil C.R., Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs 1998, 7:1475-1482.
25. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991, 146:431-437.
26. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin. Biol. Ther. 2009, 9:1057-1071.
27. Lin M.T., Lin K.W., Young M.S. Effects of body temperature on cardiovascular functional parameters in rats. J. Therm. Biol. 1994, 19:123-128.
28. Mata E., Salvador A., Igartua M., Hernández R.M., Pedraz J.L. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed. Res. Int. 2013, 2013:282913.
29. Mbawuike I., Zang Y., Couch R.B. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 2007, 25:3263-3269.
30. Mesa C., Fernández L.E. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell. Biol. 2004, 82:644-650.
31. Montomoli E., Piccirella S., Khadang B., Mennitto E., Camerini R., De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert Rev. Vaccines 2011, 10:1053-1061.
32. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., Planty C., Elouahabi A., Harvengt P., Carlsen H., et al. Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
33. Murphy D.J. Comprehensive non-clinical respiratory evaluation of promising new drugs. Toxicol. Appl. Pharmacol. 2005, 207:S414-S424.
34. Murphy D.J. Respiratory safety pharmacology - current practice and future directions. Regul. Toxicol. Pharmacol. 2013, 69:135-140.
35. Ollerstam A., Visser S.A., Duker G., Forsberg T., Persson A.H., Nilsson L.B., Björkman J.A., Gabrielsson J., Al-Saffar A. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. J. Pharmacol. Toxicol. Methods 2007, 56:131-144.
36. 42 formulated with novel adjuvants or with alum. Vaccine 2004, 22:3831-3840.
37. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 2011, 11:865-872.
38. Reeve L., Baldrick P., Hewings S., Skinner M. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy. J. Appl. Toxicol. 2012, 32:608-616.
39. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59™ adjuvant. Vaccine 2008, 26:3209-3222.
40. Segal L., Wilby O.K., Willoughby C.R., Veenstra S., Deschamps M. Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. Reprod. Toxicol. 2011, 31:111-120.
41. Sun Y., Gruber M., Matsumoto M. Overview of global regulatory toxicology requirements for vaccines and adjuvants. J. Pharmacol. Toxicol. Methods 2012, 65:49-57.
42. Tattersall M.L., Dymond M., Hammond T., Valentin J.P. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. J. Pharmacol. Toxicol. Methods 2006, 53:11-19.
43. Tontodonati M., Fasdelli N., Dorigatti R. An improved method of electrode placement in configuration Lead II for the reliable ECG recording by telemetry in the conscious rat. J. Pharmacol. Toxicol. Methods 2011, 63:1-6.
44. US Food and Drug Administration Approval Letter- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted November 22, 2013, (Accessed 12.09.14.). http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm376462.htm.
45. van der Linde H.J., Van Deuren B., Teisman A., Towart R., Gallacher D.J. The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br. J. Pharmacol. 2008, 154:1474-1481.
46. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., Anderson C., Kensil C.R. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19:3957-3967.
47. Walker W.T., Faust S.N. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines 2010, 9:1385-1398.
48. WHO WHO guidelines on nonclinical evaluation of vaccines. World Health Organ. Tech. Rep. Ser. 2005, 927:31-63.
49. WHO Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines (Final) 2013, World Health Organization, Geneva, Switzerland, 10.01.14.
50. Wiester M.J., Costa D.L., Tepper J.S., Winsett D.W., Slade R. Agonist-mediated airway challenge: cardiopulmonary interactions modulate gas exchange and recovery. Respir. Physiol. Neurobiol. 2005, 145:183-199.